Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - The Lancet, 2017 - thelancet.com
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Save Cite Cited by 967 Related articles
[PDF] academia.edu

[PDF][PDF] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - 2017 - academia.edu
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, O Inge Christoffer, GL Goll, M Lorentzen… - 2017 - ntnuopen.ntnu.no
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite
[PDF] researchgate.net

[PDF][PDF] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - Lancet, 2017 - researchgate.net
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll… - Lancet (London …, 2017 - pubmed.ncbi.nlm.nih.gov
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - The Lancet, 2017 - Elsevier
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite

[CITATION][C] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - The Lancet, 2017 - cir.nii.ac.jp
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment
with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority …
Cite

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll… - Lancet (London …, 2017 - europepmc.org
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …

KK Jørgensen, IC Olsen, GL Goll, M Lorentzen… - The Lancet, 2017 - thelancet.com
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Cite